Shareholders Equity: The sum of preferred and common equity items.
ArriVent BioPharma, Inc. (AVBP) had Shareholders Equity of $257.65M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-80.49M |
|
-- |
|
-- |
|
$94.31M |
|
$-94.31M |
|
$13.82M |
|
$-80.49M |
|
$-80.49M |
|
$-80.49M |
|
$-80.49M |
|
$-80.49M |
|
$-80.49M |
|
$-94.31M |
|
$-94.31M |
|
31.47M |
|
31.47M |
|
$-2.56 |
|
$-2.56 |
|
| Balance Sheet Financials | |
$226.98M |
|
-- |
|
$47.96M |
|
$274.94M |
|
$17.27M |
|
-- |
|
$0.01M |
|
$17.29M |
|
$257.65M |
|
$257.65M |
|
|
Shareholders Equity |
$257.65M |
33.71M |
|
| Cash Flow Statement Financials | |
$-70.21M |
|
$-192.47M |
|
$186.58M |
|
$150.39M |
|
$74.29M |
|
$-76.10M |
|
$3.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-70.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.24% |
|
-31.24% |
|
-29.27% |
|
-31.24% |
|
$7.64 |
|
$-2.23 |
|
$-2.23 |
|